Parsippany Chapter Upcoming Events Join PCCI



An early stage, clinical pre-revenue company

Presenter: Frank Minella, Founder & CEO


Tuesday, January 19, 2016

Embassy Suites, Chesterbrook, Pennsylvania (directions)




PainQx is an early stage, clinical pre-revenue company. In collaboration with the NYU School of Medicine, it is developing a way to accurately and objectively measure pain in humans and animals. The company's patented technology provides an accurate pain score in real time. It is cloud-based software, delivered to clinical users on pay-per-use or subscription basis. It is accurate, objective and consistent in contrast to the subjective, patient self report 0-10 scale (e.g. VAS or NRS).


More than 116 million people suffer from chronic pain in the US every year representing over $2 billion market potential. 


Pain assessment relies entirely on subjective patient self report. Accurate pain measurement is critical for proper medical diagnosis and treatment, yet practitioners and researchers do not have a way to objectively measure pain.


PainQx is a powerful clinical tool that solves three problems:

  1. Subjective pain management through inaccurate patient self-report
  2. Measurement of pain in patient populations that cannnot accurately articulate or express pain (e.g. unconscious, pediatric, elderly) or are unlikely to accurately describe pain level (e.g. misusers/abusers of prescribed meds).
  3. Under-treatment / Over-treatment of patient pain, especially regarding over use of opioid/analgesic drugs.


PainQx empowers and guides healthcare providers in:

  • Accurate Pain Assessment: confirms the actual level of pain in patients.
  • Effective Pain Management: guides appropriate treatments.
  • Appropriate Application: supports appropriate application of analgesic drugs.

The PainQx System is a SaaS healthcare model which analyzes, decodes and quantifies brain electric activity through patented algorithms to produce an accurate pain score in real time.



3 Major Issues


  1. PainQx plans to enter the clinical trial market first, followed by the private nursing home market, followed by the pain clinic market, followed by the major hospital markets. What are the pros and cons of using a market segmentation approach to grow the company?
  2. What is the best strategy for entering the clinical trial market?
  3. Can you provide an assessment of "need" vs "want" for pursuit of non-dilutive funding sources like SBIR or DOD grants?



6:30 - Cocktails & Dinner (Cash bar and special 2-entree buffet menu)

8:00 - Frank Minella, Founder & CEO, will deliver the Company's "Elevator" Pitch to the Group

8:20 - A Panel will address three major issues crucial to helping the Company reach the next level.

9:00 - Open discussion: members and guests



Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.



None available at this time


None available at this time


None available at this time


PainQx Webcast - 01/19/16


0:00:00  Presentation begins
0:40:35  Rob Dhoble panelist comments
0:46:13  Linda Lojewski panelist comments
0:59:25  Todd Abrams panelist comments

1:07:35  Audience comments

Contact Info:



Our Sponsors

EisnerAmperIdeas x Innovation Network i2nNew Jersey Institute of TechnologyScience Center


<Top of the page>





Questions or Coments?

Contact: Peter van der Kam, | (610) 296-8086




Good Company! Good Drink! Good Food! Good Program! Good Fun!


Site Navigation



Pharmaceutical Consulting Consortium International, Inc., or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2017



Tat Communication Inc